-
Express Advanced colorectal cancer overall survival is extended by 3 times! Results of mRNA vaccines that effectively treat "cold" tumors are out
Time of Update: 2023-01-06
▎WuXi AppTec content team editorGritstone bio recently announced the latest data from its Phase 1/2 clinical trial of its individualized cancer vaccine GRANITE combined with immune checkpoint inhibito
-
Express Advanced colorectal cancer overall survival is extended by 3 times! Results of mRNA vaccines that effectively treat "cold" tumors are out
Time of Update: 2023-01-06
▎WuXi AppTec content team editorGritstone bio recently announced the latest data from its Phase 1/2 clinical trial of its individualized cancer vaccine GRANITE combined with immune checkpoint inhibito
-
KN026 Second-line treatment of HER2-expressing gastric cancer or gastroesophageal junction cancer
Time of Update: 2023-01-05
Suzhou, China, November 23, 2022 – Corning Jerry Biopharmaceuticals (stock code: 9966. HK) and CSPC Pharmaceutical Group (stock code: 1093. HK) HK) jointly announced that the results of the phase II.
-
The results of KN026 second-line treatment of HER2-expressing gastric cancer or gastroesophageal
Time of Update: 2023-01-01
About KN026 KN026 is a HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights, which can bind two non-overlapping epitopes of HER2 at the same time, resulting in HER2 signal blockade, which is better than the combination of trastuzumab and pertuzumab, such as showing higher affinity, and has a potent tumor suppressor effect in HER2-positive tumor cell lines.
-
Express significantly improved psoriasis symptoms with positive Phase 2 clinical results of TYK2 inhibitors
Time of Update: 2023-01-01
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec Content Team Editor Not long ago, Nimbus Therapeutics released positive top-line results of a selective tyrosine kinase 2 (TYK2) allosteric inhibitor in a Phase 2b clinical trial.
-
Express significantly improved many liver function indicators, and the early clinical results of severe liver disease treatment drugs were positive
Time of Update: 2022-12-04
▎WuXi AppTec Content Team Editor Recently, Galecto released the top-line data and additional analysis results of the clinical phase 1b/2a trial of its liver disease treatment drug GB1211, which significantly improved the level of a variety of liver enzymes and biomarkers related to the progression and prognosis of liver disease。 Liver diseases, such as liver fibrosis or cirrhosis, are a global health burden.
-
Express significantly improves the symptoms of drowsiness, and innovative therapies show positive clinical results
Time of Update: 2022-11-15
Image source: 123RFThe Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pitolisant in PWS patients with primary endpoints of change in ESS-CHAD parent/caregiver version scores from baseline to end of treatment (EOT).
-
Express The Phase 3 clinical results of refractory blood cancer therapy are eye-catching, and a regulatory application will be submitted soon
Time of Update: 2022-11-15
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorActinium Pharmaceuticals today announced positive top-line results in its pivotal Phase 3 clinical trial of targeted radiotherapy Iomab-B.
-
Express prevents multiple sclerosis progression for nearly four years! T cell therapy has shown excellent results
Time of Update: 2022-11-05
▎WuXi AppTec content team editor Atara Biotherapeutics has updated new advances in its Phase 1 clinical trial of ATA188, an allogeneic T-cell immunotherapy targeting Epstein-Barr virus (EBV), in progressive multiple sclerosis, including new magnetic resonance imaging (MRI) biomarkers and open-label extension (OLE) trial data.
-
Express 98.6% reduction in recurrence risk! AstraZeneca's Phase 3 clinical results for autoimmune disease therapy are impressive
Time of Update: 2022-11-05
▎WuXi AppTec content team editorToday, AstraZeneca announced positive results from a Phase 3 clinical trial of Ulomiris (ravulizumab), a long-acting complement C5 protein inhibitor developed by its subsidiary Alexion, in the treatment of neuromyelitis optica spectrum disease (NMOSD).
-
Express HPV-positive refractory tumor patients have improved their survival by more than 4 times
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editor recently, PDS Biotechnology has published interim data from an expanded Phase 2 clinical trial of an investigational triple therapy for advanced human papillomavirus (HPV)-positive cancer, including its lead drug candidate, PDS0101.
-
Express psoriasis symptoms are significantly alleviated! Phase 1 trials of oral IL-17 inhibitors have yielded positive results
Time of Update: 2022-10-20
▎WuXi AppTec content team editor A few days ago, DICE Therapeutics announced that its oral inhibitor DC-806, which targets IL-17, has achieved positive results in a phase 1 clinical trial 。 These resu
-
Express More than eighty percent of patients achieve clinical remission! Phase 2 clinical results of long-acting GLP-2 agonists are excellent
Time of Update: 2022-10-20
Data analysis showed that about eighty percent of patients with short bowel syndrome (SBS-IF) with bowel failure achieved remission and did not require intravenous support for at least 1 day of 6 months of treatment.
-
Express For the treatment of chronic lymphocytic leukemia, BeiGene BTK inhibitor phase 3 clinical results are positive
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorToday, BeiGene announced that its Bruton's tyrosine kinase (BTK) small molecule inhibitor, BRUKINSA (zebrutinib), has achieved positive results in a global Phase 3 clinical trial called ALPINE, where zebrutinib has achieved progression-free survival (PFS) results in the treatment of chronic lymphocytic leukemia (CLL) compared with active control BTK inhibitors by an independent review committee (IRC) and investigators.
-
Express For the treatment of ulcerative enteritis, Janssen announces the latest clinical results of innovative antibody therapy
Time of Update: 2022-10-20
▎WuXi AppTec content team editorToday, Janssen, a subsidiary of Johnson & Johnson, announced the results of a Phase 2a clinical trial of its anti-IL-23 antibody guselkumab in combination with the anti-TNFα antibody golimumab for the treatment of moderate to severe ulcerative enteritis (UC).
